Wellington Management Group LLP Sells 159,972 Shares of GSK plc (NYSE:GSK)

Wellington Management Group LLP cut its holdings in GSK plc (NYSE:GSK - Free Report) by 7.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,904,058 shares of the pharmaceutical company's stock after selling 159,972 shares during the quarter. Wellington Management Group LLP owned about 0.09% of GSK worth $77,838,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its stake in shares of GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock valued at $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC boosted its position in shares of GSK by 14.3% in the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company's stock valued at $16,747,000 after purchasing an additional 51,378 shares during the period. Cerity Partners LLC increased its stake in GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company's stock worth $17,728,000 after purchasing an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC raised its holdings in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company's stock worth $20,460,000 after buying an additional 83,433 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Insider Activity

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the business's stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares of the company's stock, valued at $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is owned by corporate insiders.

GSK Stock Down 2.2 %

Shares of NYSE GSK traded down $0.77 during mid-day trading on Wednesday, reaching $34.44. The company had a trading volume of 3,951,178 shares, compared to its average volume of 4,165,458. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92. The stock's 50 day moving average is $36.46 and its 200-day moving average is $39.43. The stock has a market capitalization of $71.37 billion, a PE ratio of 22.53, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. The ex-dividend date of this dividend is Friday, November 15th. This is an increase from GSK's previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.56%. GSK's dividend payout ratio (DPR) is 99.35%.

Wall Street Analysts Forecast Growth

GSK has been the subject of several recent analyst reports. Barclays upgraded shares of GSK to a "hold" rating in a report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and cut their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim cut GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Finally, StockNews.com lowered GSK from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 4th. Seven research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.